Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Filgrastim Compared With Filgrastim-SD/01 Following Combination Chemotherapy in Treating Patients With Newly Diagnosed Sarcoma
This study is ongoing, but not recruiting participants.
Study NCT00020137 Information provided by National Cancer Institute (NCI)
First Received: July 11, 2001 Last Updated: July 15, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiac Toxicity
Neutropenia
Sarcoma
Additional conditions recognized in this trial
Neuroectodermal Tumors, Primitive, Peripheral
More general conditions related to this trial
Agranulocytosis
Hematologic Diseases
Leukocyte Disorders
Leukopenia
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Interventions listed in this trial
filgrastim
pegfilgrastim
cyclophosphamide
dexrazoxane hydrochloride
doxorubicin hydrochloride
etoposide
ifosfamide
vincristine sulfate
Additional drug interventions recognized in this trial
Doxorubicin
Razoxane
Vincristine
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Cardiovascular Agents
Chelating Agents
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
